Aqua: A new questionnaire assessing anticholinergic side effects in neurogenic population (Aqua: Anticholinergic side effects questionnaire).
Prog Urol
; 32(11): 751-755, 2022 Sep.
Article
en En
| MEDLINE
| ID: mdl-35729028
ABSTRACT
AIMS:
Validate a new questionnaire to assess the side effects secondary to anticholinergics in neurogenic population suffering from Adult neurogenic lower urinary tract dysfunction (ANLUTD).METHODS:
We conducted a prospective, monocentric study in a Neuro-urology Department of a University Hospital between February 2015 and April 2020. To allow a full psychometric validation of a questionnaire, the study protocol included 3steps:
qualitative interviews, feasibility study and validation study. The primary outcome was good psychometric properties defined with good internal consistency reliability (Cronbach's α>0.7) and good test-retest reliability (intraclass correlation coefficient (ICC)>0.7).RESULTS:
we included 64 patients with ANLUTD secondary to neurogenic disorders. Feasibility study demonstrate very good acceptation and comprehension for 97% of patients. Validation study showed good internal consistency with Cronbach's α=0,69 and very good ICC=0,73. AQUA is composed with 8 items scoring 0 (no side effect) to 2 (major side effect) for a total score between 0 to 16. Time to fulfill is very quick. Mean score in our population was 4,1 (sd 2,9).CONCLUSION:
AQUA is the first validated tool to assess side effects secondary to antimuscarinic treatment for neurogenic population suffering from ANLUTD. LEVEL OF PROOF 2.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Antagonistas Colinérgicos
/
Enfermedad Iatrogénica
Tipo de estudio:
Guideline
/
Observational_studies
/
Qualitative_research
Límite:
Adult
/
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Article